ImmuneSpec BV

Startup

ImmuneSpec is a biotech company founded in 2023 as a spin-off from the University of Antwerp, specializing in advanced immunopeptidomics. Our state-of-the-art mass spectrometry (MS)-based platform precisely identifies antigens presented on the cell surface, offering key insights into antigen processing and presentation.

By mapping MHC-bound peptides with high resolution, we support the discovery of neoantigens for cancer immunotherapy and contribute to the development of highly protective, broad-spectrum vaccines. Our approach enables the characterization of pathogen-derived epitopes and mutation-associated peptides, aiding in rational antigen selection for therapeutic and prophylactic applications.

In addition to identifying immunogenic targets, ImmuneSpec assesses unwanted immunogenicity of biotherapeutics during preclinical development. By analyzing MHC-associated peptides, our platform provides insights that support the optimization of biologics for improved safety and efficacy.

Through construct validation, we confirm antigen presentation to ensure that therapeutic candidates are correctly processed and displayed on MHC molecules, supporting their further development.

With a commitment to excellence in immunopeptidomics for better and safer biotherapeutics, we provide high-resolution molecular insights that benefit any biotech company developing biotherapeutics.

website